Latest Car T News

Eagers Automotive delivered a record $13 billion revenue in 2025, boosted market share in new and New Energy Vehicles, and secured landmark global partnerships to fuel future growth.

Harmoney has reaffirmed its FY26 cash NPAT guidance of $13 million, propelled by robust loan origination growth, margin improvements, and operational efficiencies from its Stellare® 2.0 platform.

AdAlta, Oribiotech, and Cell Therapies have inked a Memorandum of Understanding to deploy Oribiotech’s IRO automated cell therapy manufacturing platform in Australia and Asia Pacific, aiming to slash costs and boost production speed for CAR-T therapies.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Transurban Group's March quarter 2026 traffic update shows a 3.0% increase in average daily traffic, driven by infrastructure openings in Melbourne and North America despite ongoing macroeconomic and geopolitical challenges.

Transurban Group's March quarter 2026 traffic update shows a 3.0% increase in average daily traffic, supported by new infrastructure openings in Melbourne and North America amid ongoing macroeconomic and geopolitical challenges.

Arovella Therapeutics has demonstrated that its novel CLDN18.2-targeting CAR incorporated into iNKT cells effectively eliminates pancreatic and gastric cancer cells in vitro, with IL-12-TM armouring enhancing potency and durability.

Eagers Automotive is broadening its Australian footprint through strategic investments in multi-brand dealerships and premium Audi outlets, while advancing its international ambitions with CanadaOne Auto.

AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.

ClearVue Technologies has achieved a key international certification for its innovative solar panels and is deepening its strategic alliance with Helios Power, setting the stage for expanded commercial deployment in the building-integrated photovoltaics market.

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.

CAR Group Limited has announced the issue price for shares under its Dividend Reinvestment Plan (DRP) at $23.409 per share for the FY26 interim dividend, reflecting recent trading activity.